Vivos Therapeutics Inc. (VVOS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Vivos Therapeutics Inc.

    NASDAQ: VVOS · Real-Time Price · USD
    3.83
    -0.29 (-7.04%)
    At close: Sep 08, 2025, 3:59 PM
    3.84
    0.26%
    After-hours: Sep 08, 2025, 07:09 PM EDT

    Vivos Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 15.03M 13.8M 16.02M 16.89M
    Cost of Revenue
    		 6.01M 5.53M 6M 4.28M
    Gross Profit
    		 9.02M 8.27M 10.02M 12.6M
    Operating Income
    		 -11.17M -17.3M -25.03M -19.47M
    Interest Income
    		 n/a n/a 89K 117K
    Pretax Income
    		 -11.14M -13.58M -23.84M -20.29M
    Net Income
    		 -11.14M -13.58M -23.84M -20.29M
    Selling & General & Admin
    		 19.61M 24.85M 34.38M 31.34M
    Research & Development
    		 n/a 100K 200K n/a
    Other Expenses
    		 581K 621K 469K 733K
    Operating Expenses
    		 20.19M 25.57M 35.05M 32.08M
    Interest Expense
    		 n/a n/a n/a 14K
    Selling & Marketing Expenses
    		 1.73M 2.47M 5.34M 5.55M
    Cost & Expenses
    		 26.2M 31.1M 41.05M 37.27M
    Income Tax Expense
    		 n/a n/a -1.19M 5K
    Shares Outstanding (Basic)
    		 5.02M 1.22M 920.48K 849.32K
    Shares Outstanding (Diluted)
    		 5.02M 1.22M 920.48K 849.32K
    EPS (Basic)
    		 -2.22 -11.14 -25.9 -23.89
    EPS (Diluted)
    		 -2.22 -11.14 -25.9 -23.89
    EBITDA
    		 -10.55M -16.68M -24.36M -19.54M
    EBIT
    		 -11.17M -17.3M -25.03M -20.27M
    Depreciation & Amortization
    		 581K 621K 669K 733K

    Add to Watchlist